Compound 860
Identifiers
- Canonical SMILES:
CC(C)c1cn(nn1)C(=O)NC[C@H](NC(=O)c1c(Cl)cc2CN(CCc2c1Cl)C(=O)c1cc2ccccc2o1)C(O)=O
- InChi:
InChI=1S/C28H26Cl2N6O6/c1-14(2)20-13-36(34-33-20)28(41)31-11-19(27(39)40)32-25(37)23-18(29)9-16-12-35(8-7-17(16)24(23)30)26(38)22-10-15-5-3-4-6-21(15)42-22/h3-6,9-10,13-14,19H,7-8,11-12H2,1-2H3,(H,31,41)(H,32,37)(H,39,40)/t19-/m0/s1
- InChiKey:
GYVWYRULTQYYOJ-IBGZPJMESA-N
External links
168318051 |
External search
Bibliography (1)
Pharmacological data
Biochemical tests | Cellular tests | PK tests | Cytotoxicity tests |
---|---|---|---|
1 | 0 | 0 | 0 |
Targets
PPI family | Best activity | Diseases | MMoA |
---|---|---|---|
LFA / ICAM | 8.30 | immune system disease | Inhibition |
Physicochemical filters
Descriptor | Lipinski's RO5 | Veber | Pfizer's 3/75 | |
---|---|---|---|---|
Compliance | ||||
MW | 612.13 g/mol | |||
HBA | 12 | |||
HBD | 3 | |||
HBA + HBD | 15 | |||
AlogP | 3.40 | |||
TPSA | 159.66 | |||
RB | 7 |
Radar chart
PCA : iPPI-DB chemical space
PCA : Correlation circle
Efficiencies: iPPI-DB biplot LE versus LLE
Summary
Bibliographic ressources | Biochemical tests | Cellular tests | PK tests | Cytotoxicity tests |
---|---|---|---|---|
1 | 1 | 0 | 0 | 0 |
Ta | Structure | Name | Drugbank ID |
---|---|---|---|
0.4904 | Lifitegrast | DB11611 | |
0.4423 | L-756423 | DB02009 | |
0.4302 | Bradanicline | DB06090 | |
0.4147 | JNJ-54175446 | DB15358 | |
0.4107 | N-[(Furan-2-Yl)Carbonyl]-(S)-Leucyl-(R)-[1-Amino-2(1h-Indol-3-Yl)Ethyl]-Phosphonic Acid | DB02046 | |
0.4034 | PF-06821497 | DB14799 | |
0.4027 | (2s)-2-[(5-Benzofuran-2-Yl-Thiophen-2-Ylmethyl)-(2,4-Dichloro-Benzoyl)-Amino]-3-Phenyl-Propionic Acid | DB02331 | |
0.3976 | Piromelatine | DB12288 | |
0.3954 | Proglumetacin | DB13527 | |
0.3946 | Histrelin | DB06788 | |
0.3918 | Taspoglutide | DB14027 | |
0.3904 | Cotadutide | DB15194 | |
0.3896 | Uprosertib | DB11969 | |
0.3854 | Icatibant | DB06196 | |
0.3836 | Afamelanotide | DB04931 |